NCT02898350CompletedNot Applicable
Multi-Center Study to Compare the Safety and Efficacy of Clearance of Surgical Scars With the Pulse Dye Laser in Combination With a CO2 Laser in a Split Scar Evaluation
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Syneron Medical
- Enrollment
- 25
- Locations
- 3
- Primary Endpoint
- Improvement in Global Evaluation Response (GER) scale for 4 study arms compared to baseline
Study Overview
Brief Summary
Prospective, randomized, split lesion treatment with 4 study Arms to evaluate safety and efficacy of combined treatment for minimizing of surgical scars, including post Moh's surgery.
Detailed Description
Prospective, Randomized, Split lesion treatment with 4 study Arms: 1) treatment with pulsed dye laser (PDL) only, 2) treatment with CO2 laser only, 3) PDL and CO2 laser combined treatment, and 4) split scar combined lasers with an additional single CO2 laser treatment immediately post-surgery vs. no treatment.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- Single (Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 85 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Comprehension of, and willingness to sign, the Informed Consent Form.
- •Have a planned a surgical procedure, which is expected to result in a least one linear surgical scar of at least 3.0 cm.
- •Be a healthy male or female of at least 18 years old.
- •Fitzpatrick skin type I-V.
- •Willingness to follow the treatment and follow-up schedule and the post-treatment care instructions.
- •Non pregnant and/or breast feeding, if applicable.
- •Willingness to provide a brief medical history including disclosure of any prescribed or over-the-counter medications taken within the past 6 months.
- •Agree to follow and undergo all study-related procedures.
- •Use of daily use of sunblock SPF 30 or higher for duration of the study.
Exclusion Criteria
- •Pregnant and/or breastfeeding.
- •Fitzpatrick skin type VI.
- •Prior treatment for the surgical scar to be treated in this study.
- •Having a history of diseases stimulated by heat, such as recurrent Herpes Simplex in the treated area, unless treatment is conducted following a prophylactic regimen.
- •Use of Isotretinoin or other systemic retinoids within the past 6 months.
- •Use of topical retinoids or therapeutic topicals in the treatment area in past 2 months.
- •Use of medications that induce photosensitivity on the 595 and 10,600 nm wavelength ranges.
- •Suffering from current or history of significant skin conditions in the treated area or inflammatory skin conditions.
- •History of immunosuppression/immune deficiency disorders or currently using immunosuppressive medications.
- •Having any uncontrolled disease or disorder or one which per the investigator's judgment might make it unsafe for the subject to participate in this study.
- •Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning and sun exposure for the duration of the study.
- •Participation in another investigational device or investigational drug study within 30 days prior to enrollment, as per the investigator's clinical judgment.
- •As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.
Outcomes
Primary Outcomes
Improvement in Global Evaluation Response (GER) scale for 4 study arms compared to baseline
Time Frame: Baseline, 3 months after final treatment
Blinded review of 7-point Global Evaluation Response (GER) scale
Secondary Outcomes
- Improvement in Vancouver Scar Scale (VSS) scale for 4 study arms compared to baseline(Baseline, 3 months after final treatment)
Investigators
Study Sites (3)
Loading locations...
Similar Trials
Terminated
Phase 4
A Study Comparing Safety and Efficacy of Levofloxacin and Metronidazole Versus Piperacillin/Tazobactam in Treating Complicated AppendicitisAppendicitisNCT00236912Johnson & Johnson Pharmaceutical Research & Development, L.L.C.139
Terminated
Phase 3
Safety & Efficacy of Corneal Collagen Cross-Linking in Eyes With Keratoconus or Corneal Ectasia After Refractive SurgeryCorneal EctasiaKeratoconusNCT01459679American-European Congress of Ophthalmic Surgery1,721
Completed
Phase 3
Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCLB-cell Non Hodgkin's LymphomaNCT02787239Shanghai Henlius Biotech407
Completed
Phase 3
Study to Assess the Efficacy and Safety of Dysport® in Cervical DystoniaCervical DystoniaNCT00447772Ipsen516
Completed
Phase 3
Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONICCrohn DiseaseNCT00094458Centocor Ortho Biotech Services, L.L.C.508